000			04115nam a22006617a 4500
008			191119s20202020 xxu||||| |||| 00| 0 eng d
022			_a0022-3166
024			_a10.1093/jn/nxz259 [doi]
024			_a5607414 [pii]
040			_aOvid MEDLINE(R)
099			_a31665380
245			_aPlasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study.
251			_aJournal of Nutrition. 150(5):1214-1222, 2020 05 01.
252			_aJ Nutr. 150(5):1214-1222, 2020 05 01.
252			_zJ Nutr. 2019 Oct 26
253			_aThe Journal of nutrition
260			_c2020
260			_fFY2020
265			_saheadofprint
265			_sppublish
266			_d2019-11-19
268			_aJournal of Nutrition. 2019 Oct 26
501			_aAvailable online from MWHC library: Sept 1928 - present (after 1 year)
520			_aBACKGROUND: Few studies have assessed the associations of ceramides and sphingomyelins (SMs) with diabetes in humans.
520			_aCONCLUSIONS: Higher concentrations of circulating Cer-18, Cer-20, and Cer-22 were associated with a higher risk of developing diabetes in 2 studies of American-Indian adults. This trial was registered at clinicaltrials.gov as NCT00005134. Copyright (c) The Author(s) 2019.
520			_aMETHODS: The analysis included 435 American-Indian participants from the Strong Heart Study (nested case-control design for analyses; mean age: 57 y; 34% male; median time until diabetes 4.3 y for cases) and 1902 participants from the Strong Heart Family Study (prospective design for analyses; mean age: 37 y; 39% male; median 12.5 y of follow-up). Sphingolipid species were measured using stored plasma samples by sequential LC and MS. Using logistic regression and parametric survival models within studies, and an inverse-variance-weighted meta-analysis across studies, we examined associations of 15 ceramides and SM species with incident diabetes.
520			_aOBJECTIVE: We assessed associations of 15 circulating ceramides and SM species with incident diabetes in 2 studies.
520			_aRESULTS: There were 446 cases of incident diabetes across the studies. Higher circulating concentrations of ceramides containing stearic acid (Cer-18), arachidic acid (Cer-20), and behenic acid (Cer-22) were each associated with a higher risk of diabetes. The RRs for incident diabetes per 1 SD of each log ceramide species (muM) were 1.22 (95% CI: 1.09, 1.37) for Cer-18, 1.18 (95% CI: 1.06, 1.31) for Cer-20, and 1.20 (95% CI: 1.08, 1.32) for Cer-22. Although the magnitude of the risk estimates for the association of ceramides containing lignoceric acid (Cer-24) with diabetes was similar to those for Cer-18, Cer-20, and Cer-22 (RR = 1.13; 95% CI: 1.01, 1.26), the association was not statistically significant after correction for multiple testing (P = 0.007). Ceramides carrying palmitic acid (Cer-16), SMs, glucosyl-ceramides, or a lactosyl-ceramide were not associated with diabetes risk.
546			_aEnglish
650			_a*Ceramides/bl [Blood]
650			_a*Diabetes Mellitus, Type 2/bl [Blood]
650			_a*Indians, North American
650			_aAdult
650			_aAged
650			_aArizona
650			_aCase-Control Studies
650			_aCeramides/ch [Chemistry]
650			_aDiabetes Mellitus, Type 2/eh [Ethnology]
650			_aFemale
650			_aFollow-Up Studies
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aNorth Dakota
650			_aOklahoma
650			_aProspective Studies
650			_aRisk Factors
650			_aSouth Dakota
650			_aSphingolipids/bl [Blood]
650			_aSphingomyelins/bl [Blood]
651			_aMedStar Health Research Institute
657			_aJournal Article
700			_aHoward, Barbara V
700			_aUmans, Jason G
790			_aFretts AM, Hoofnagle A, Howard BV, Jensen PN, King IB, Lemaitre RN, McKnight B, Siscovick DS, Sitlani C, Sotoodehnia N, Umans J, Yu C
856			_uhttps://dx.doi.org/10.1093/jn/nxz259 _zhttps://dx.doi.org/10.1093/jn/nxz259
942			_cART _dArticle
999			_c4729 _d4729